Oral Session

[OR2] Oral Session ⅡCancer①

Thu. Jul 14, 2022 1:30 PM - 2:42 PM Room 3 (3F 304)

Chair persons : Kosai Kenichiro（Kagoshima University Graduate School of Medical and Dental Sciences）,Hiroshi Tazawa（Center for Innovative Clinical Medicine, Okayama University Hospital)

+Add all to schedule

[OR-14] Efficacy of a third-generation oncolytic herpes simplex virus type 1 in patient-derived sarcoma cells

Satoru Taguchi (Department of Urology, Graduate School of Medicine, The University of Tokyo)

[OR-15] The mechanism of novel oncolytic adenovirus serotype 35-mediated anti-tumor effects

Ryosuke Ono (Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University)

[OR-16] Immunization with adenovirus-p53-transduced dendritic cell vaccine enhances the antitumor efficacy of p53-armed oncolytic virotherapy in colorectal cancer

Motohiko Yamada (Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan)

[OR-17] Suicide gene therapy for canine malignancies by using retroviral replicating vectors.

Emiko Sonoda (Laboratory of Molecular and Genetic Therapeutics, Advanced Medical Science, Hyogo Medical University)

[OR-18] Development of a novel CAR-T cell therapy targeting insulin-like growth factor I receptor for lung adenocarcinoma

Shuji Mishima (Division of General Thoracic Surgery, Department of Surgery, Shinshu University school of medicine)

[OR-19] STING Activator 2’3’-cGAMP Enhances the Anti-tumor Efficacy of C-REV, an HSV1 based Oncolytic Virus

Patricia Angela Alvero Sibal (Nagoya University School of Science /Nagoya University Graduate School of Medicine Cancer Immune Therapy Research Center)